Woodrow J C, Clarke C A, McConnell R B, Towers S H, Donohoe W T
Br Med J. 1971 Jun 12;2(5762):610-2. doi: 10.1136/bmj.2.5762.610.
A clinical trial is reported in which Rh-negative primiparae, just delivered of an Rh-positive ABO-compatible infant and in whom fetal cell counts after delivery suggested less than 0.2 ml of circulating fetal blood, were treated with about 200 mug of anti-D gammaglobulin. Three (0.36%) out of 844 women thus treated developed anti-D in the subsequent six months; this is 10% of the incidence in untreated controls. Three (1.8%) out of 171 treated mothers had anti-D at the end of the second Rh-positive pregnancy, and this is 18% of the incidence in controls.Possible reasons for the occasional failure of the treatment are discussed and the results of this trial are compared with those of a previous trial in which 1,000 mug or more of anti-D was given to a different group of mothers. The combined results of the two trials lead to the conclusion that the passive administration of anti-D gammaglobulin after delivery affords in this population of Rh-negative women a 95% protection rate in the postdelivery period and an 89% protection rate by the end of the subsequent pregnancy.
本文报告了一项临床试验，试验对象为分娩出Rh阳性且ABO血型相容婴儿的Rh阴性初产妇，这些产妇分娩后胎儿细胞计数提示循环胎儿血量少于0.2毫升，她们接受了约200微克抗-D丙种球蛋白治疗。在接受治疗的844名女性中，有3名（0.36%）在随后六个月内产生了抗-D；这是未治疗对照组发病率的10%。在171名接受治疗的母亲中，有3名（1.8%）在第二次Rh阳性妊娠结束时产生了抗-D，这是对照组发病率的18%。文中讨论了治疗偶尔失败的可能原因，并将本试验结果与先前一项试验的结果进行了比较，在先前试验中，另一组母亲接受了1000微克或更多的抗-D治疗。两项试验的综合结果得出结论，分娩后被动给予抗-D丙种球蛋白，在这群Rh阴性女性中，产后阶段的保护率为95%，到随后妊娠结束时的保护率为89%。
